Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients
2021 · Transplantation and Cellular Therapy · 54 citations
https://doi.org/10.1016/j.jtct.2021.07.005
L
Leyla Shune
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
381
Papers
2.5K
Citations
25
h-index
56
i10-index
Leyla Shune is an academic researcher from University of Kansas. The author has contributed to research in topics: CAR-T cell therapy research & Multiple Myeloma Research and Treatments & Hematopoietic Stem Cell Transplantation. The author has an h-index of 25, co-authored 324 publications.
ORCID: 0000-0003-1650-1873Papers by this author
worksImpact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel
2024 · Journal of Hematology & Oncology · 39 citations
https://doi.org/10.1186/s13045-024-01555-4
Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium
2024 · Blood Cancer Journal · 29 citations
https://doi.org/10.1038/s41408-024-00993-0
Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy
2024 · Blood Cancer Journal · 19 citations
https://doi.org/10.1038/s41408-024-01197-2
Retrospective evaluation of fidaxomicin versus oral vancomycin for treatment of Clostridium difficile infections in allogeneic stem cell transplant
2018 · Hematology/Oncology and Stem Cell Therapy · 13 citations
https://doi.org/10.1016/j.hemonc.2018.05.001
Hospitalization at the end of life in patients with multiple myeloma
2021 · BMC Cancer · 13 citations
https://doi.org/10.1186/s12885-021-08079-x
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat